UNSPSC 51332825: Pipotiazine

This classification denotes an antipsychotic agent with the molecular formula C24H33N3O3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L903J9JPYV, chemically known as 10h-phenothiazine-2-sulfonamide,10-(3-(4-(2-hydroxyethyl)-1-piperidinyl)propyl)-n,n-dimethyl- but generally known as pipotiazine, which bears US NIH Compound Identifier 62867. European Medicines Agency schedules Pipotiazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09879MIG.

UNSPSC 51332825 Pipotiazine, a Commodity code, shows minimal recent activity aligned with its nominal scope; the three opportunities posted since early 2026 address broader pharmaceutical procurement (naloxone and safe drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products) rather than pipotiazine specifically. State and local governments buying under this code segment procure pharmaceutical products through county health departments, state health and human services commissions, and cooperative purchasing alliances, typically on fixed-fee or competitive-bid bases with quarterly or annual delivery cycles and compliance requirements including cGMP certification, Drug Supply Chain Security Act adherence, and federal regulatory alignment.

Recent opportunities span Florida, Texas, and Minnesota—Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for the Seminole County Community Health Building with quarterly deliveries and potential FEMA funding; the Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 (response due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with awarded vendors required to work through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC.